Product
ALE.F02
2 clinical trials
3 indications
Indication
Rapidly Progressive GlomerulonephritisIndication
advanced liver fibrosisIndication
CirrhosisClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive GlomerulonephritisStatus: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild CirrhosisStatus: Recruiting, Estimated PCD: 2024-11-30